BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Trojan J, Schroeder O, Raedle J, Baum RP, Herrmann G, Jacobi V, Zeuzem S. Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma. Am J Gastroenterol. 1999;94:3314-3319. [PMID: 10566736 DOI: 10.1111/j.1572-0241.1999.01544.x] [Cited by in Crossref: 180] [Cited by in F6Publishing: 144] [Article Influence: 7.8] [Reference Citation Analysis]
Number Citing Articles
1 Ansari D, Keussen I, Andersson R. Positron emission tomography in malignancies of the liver, pancreas and biliary tract – indications and potential pitfalls. Scandinavian Journal of Gastroenterology 2012;48:259-65. [DOI: 10.3109/00365521.2012.704936] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
2 Yun M, Bang SH, Kim JW, Park JY, Kim KS, Lee JD. The importance of acetyl coenzyme A synthetase for 11C-acetate uptake and cell survival in hepatocellular carcinoma. J Nucl Med. 2009;50:1222-1228. [PMID: 19617323 DOI: 10.2967/jnumed.109.062703] [Cited by in Crossref: 61] [Cited by in F6Publishing: 58] [Article Influence: 4.7] [Reference Citation Analysis]
3 Yang SH, Suh K, Lee HW, Cho E, Cho JY, Cho YB, Yi N, Lee KU. The role of18F-FDG-PET imaging for the selection of liver transplantation candidates among hepatocellular carcinoma patients. Liver Transpl 2006;12:1655-60. [DOI: 10.1002/lt.20861] [Cited by in Crossref: 112] [Cited by in F6Publishing: 102] [Article Influence: 7.0] [Reference Citation Analysis]
4 Ijichi H, Shirabe K, Taketomi A, Yoshizumi T, Ikegami T, Mano Y, Aishima S, Abe K, Honda H, Maehara Y. Clinical usefulness of (18) F-fluorodeoxyglucose positron emission tomography/computed tomography for patients with primary liver cancer with special reference to rare histological types, hepatocellular carcinoma with sarcomatous change and combined hepatocellular and cholangiocarcinoma. Hepatol Res. 2013;43:481-487. [PMID: 23145869 DOI: 10.1111/j.1872-034x.2012.01107.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
5 Song MJ, Bae SH, Yoo IR, Park CH, Jang JW, Chun HJ, Choi BG, Lee HG, Choi JY, Yoon SK. Predictive value of 18F-fluorodeoxyglucose PET/CT for transarterial chemolipiodolization of hepatocellular carcinoma. World J Gastroenterol 2012; 18(25): 3215-3222 [PMID: 22783045 DOI: 10.3748/wjg.v18.i25.3215] [Cited by in F6Publishing: 15] [Reference Citation Analysis]
6 Ho CL, Chen S, Cheung SK, Leung TWT. Significant Value of 11C-Acetate and 18F-Fluorodeoxyglucose PET/Computed Tomography on 90Y Microsphere Radioembolization for Hepatocellular Carcinoma. PET Clinics 2019;14:459-67. [DOI: 10.1016/j.cpet.2019.06.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
7 Fournier LS, Cuenod CA, de Bazelaire C, Siauve N, Rosty C, Tran PL, Frija G, Clement O. Early modifications of hepatic perfusion measured by functional CT in a rat model of hepatocellular carcinoma using a blood pool contrast agent. Eur Radiol. 2004;14:2125-2133. [PMID: 15503038 DOI: 10.1007/s00330-004-2339-8] [Cited by in Crossref: 57] [Cited by in F6Publishing: 51] [Article Influence: 3.2] [Reference Citation Analysis]
8 Delbeke D, Martin WH. Update of PET and PET/CT for hepatobiliary and pancreatic malignancies. HPB (Oxford). 2005;7:166-179. [PMID: 18333185 DOI: 10.1080/13651820510028909] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
9 Verhoef C, Valkema R, De Man RA, Krenning EP, Yzermans JNM. Fluorine-18 FDG imaging in hepatocellular carcinoma using positron coincidence detection and single photon emission computed tomography: Fluorine-18 FDG imaging in hepatocellular carcinoma. Liver 2002;22:51-6. [DOI: 10.1046/j.0106-9543.2001.01593.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
10 Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, Kudo M, Lee JM, Choi BI, Poon RT, Shiina S, Cheng AL, Jia JD, Obi S, Han KH, Jafri W, Chow P, Lim SG, Chawla YK, Budihusodo U, Gani RA, Lesmana CR, Putranto TA, Liaw YF, Sarin SK. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010;4:439-74. [PMID: 20827404 DOI: 10.1007/s12072-010-9165-7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Hatori A, Yui J, Xie L, Yamasaki T, Kumata K, Fujinaga M, Wakizaka H, Ogawa M, Nengaki N, Kawamura K, Zhang MR. Visualization of acute liver damage induced by cycloheximide in rats using PET with [(18)F]FEDAC, a radiotracer for translocator protein (18 kDa). PLoS One 2014;9:e86625. [PMID: 24466178 DOI: 10.1371/journal.pone.0086625] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
12 Miller G, Schwartz LH, D'Angelica M. The use of imaging in the diagnosis and staging of hepatobiliary malignancies. Surg Oncol Clin N Am. 2007;16:343-368. [PMID: 17560517 DOI: 10.1016/j.soc.2007.04.001] [Cited by in Crossref: 35] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
13 Park JW, Kim JH, Kim SK, Kang KW, Park KW, Choi JI, Lee WJ, Kim CM, Nam BH. A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma. J Nucl Med. 2008;49:1912-1921. [PMID: 18997056 DOI: 10.2967/jnumed.108.055087] [Cited by in Crossref: 169] [Cited by in F6Publishing: 139] [Article Influence: 12.1] [Reference Citation Analysis]
14 Tsurusaki M, Okada M, Kuroda H, Matsuki M, Ishii K, Murakami T. Clinical application of 18F-fluorodeoxyglucose positron emission tomography for assessment and evaluation after therapy for malignant hepatic tumor. J Gastroenterol 2014;49:46-56. [PMID: 23525980 DOI: 10.1007/s00535-013-0790-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
15 Swiętaszczyk C, Pilecki SE. To what extent can diverse types of liver lesions mimic hemangiomas? A retrospective quantitative analysis of masses found to be positive in SPECT/CT with labeled blood cells - a preliminary report. Pol J Radiol 2013;78:21-6. [PMID: 24511318 DOI: 10.12659/PJR.889225] [Reference Citation Analysis]
16 Song MJ. Bae SH, Lee SW, Song DS, Kim HY, Yoo IeR, Choi JI, Lee YJ, Chun HJ, Lee HG, Choi JY, Yoon SK. 18F-fluorodeoxyglucose PET/CT predicts tumour progression after transarterial chemoembolization in hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2013;40:865-873. [PMID: 23436073 DOI: 10.1007/s00259-013-2366-2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 3.6] [Reference Citation Analysis]
17 Rachh S, Basu S. PET/CT in patients with liver lesions of different nature. Clin Transl Imaging 2014;2:139-55. [DOI: 10.1007/s40336-014-0061-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
18 Lee JE, Jang JY, Jeong SW, Lee SH, Kim SG, Cha SW, Kim YS, Cho YD, Kim HS, Kim BS, Jin SY, Choi DL. Diagnostic value for extrahepatic metastases of hepatocellular carcinoma in positron emission tomography/computed tomography scan. World J Gastroenterol 2012; 18(23): 2979-2987 [PMID: 22736922 DOI: 10.3748/wjg.v18.i23.2979] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
19 Ahn SG, Kim SH, Jeon TJ, Cho HJ, Choi SB, Yun MJ, Lee JD, Kim KS. The role of preoperative [18F]fluorodeoxyglucose positron emission tomography in predicting early recurrence after curative resection of hepatocellular carcinomas. J Gastrointest Surg. 2011;15:2044-2052. [PMID: 21904962 DOI: 10.1007/s11605-011-1660-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 2.3] [Reference Citation Analysis]
20 Gil Martínez EM, Rabadán Bujalance F, Ponce Herrera C, Martínez Obrador D, Moya García F. [FDG-PET in hepatocellular carcinoma. Based on one case]. Rev Esp Med Nucl 2004;23:352-3. [PMID: 15450142 DOI: 10.1016/s0212-6982(04)72316-2] [Reference Citation Analysis]
21 Toshima T, Taketomi A, Shirabe K, Takeishi K, Motomura T, Mano Y, Morita K, Fukuhara T, Sugimachi K, Maruoka Y, Abe K, Tajima T, Maehara Y. Solitary Asymptomatic Thyroid Metastasis from Hepatocellular Carcinoma Detected by FDG-PET/CT. Case Rep Gastroenterol 2010;4:279-85. [PMID: 21383951 DOI: 10.1159/000318858] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
22 Hustinx R. PET imaging in assessing gastrointestinal tumors. Radiologic Clinics of North America 2004;42:1123-39. [DOI: 10.1016/j.rcl.2004.08.003] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
23 Huang WY, Kao CH, Huang WS, Chen CM, Chang LP, Lee MS, Chao HL, Chiu CH, Lo CH, Jen YM. 18F-FDG PET and combined 18F-FDG-contrast CT parameters as predictors of tumor control for hepatocellular carcinoma after stereotactic ablative radiotherapy. J Nucl Med. 2013;54:1710-1716. [PMID: 23970365 DOI: 10.2967/jnumed.112.119370] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
24 Moadel RM, Blaufox MD, Freeman LM. The role of positron emission tomography in gastrointestinal imaging. Gastroenterol Clin North Am 2002;31:841-61. [PMID: 12481734 DOI: 10.1016/s0889-8553(02)00035-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
25 Kurtovic J, Van Der Wall H, Riordan SM. FDG PET for discrimination between tumor extension and blood thrombus as a cause for portal vein thrombosis in hepatocellular carcinoma: important role in exclusion of transplant candidacy. Clin Nucl Med. 2005;30:408-410. [PMID: 15891293 DOI: 10.1097/01.rlu.0000162606.83862.a7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
26 Peng F, Liu J, Wu JS, Lu X, Muzik O. Mouse extrahepatic hepatoma detected on MicroPET using copper (II)-64 chloride uptake mediated by endogenous mouse copper transporter 1. Mol Imaging Biol 2005;7:325-9. [PMID: 16220354 DOI: 10.1007/s11307-005-0021-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
27 Khandani AH, Wahl RL. Applications of PET in Liver Imaging. Radiologic Clinics of North America 2005;43:849-60. [DOI: 10.1016/j.rcl.2005.05.008] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
28 Yang L, Marx H, Yen Y. Early finding of chest wall metastasis of hepatocellular carcinoma in a woman by fluorodeoxyglucose-positron emission tomography scan: a case report. J Med Case Rep 2011;5:147. [PMID: 21489297 DOI: 10.1186/1752-1947-5-147] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
29 Braga FJ, Flamen P, Mortelmans L, Stroobants S, Homans F, Maes A. Ga-67-positive and F-18 FDG-negative imaging in well-differentiated hepatocellular carcinoma. Clin Nucl Med 2001;26:642. [PMID: 11416755 DOI: 10.1097/00003072-200107000-00020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
30 Nagaoka S, Itano S, Ishibashi M, Torimura T, Baba K, Akiyoshi J, Kurogi J, Matsugaki S, Inoue K, Tajiri N, Takada A, Ando E, Kuromatsu R, Kaida H, Kurogi M, Koga H, Kumashiro R, Hayabuchi N, Kojiro M, Sata M. Value of fusing PET plus CT images in hepatocellular carcinoma and combined hepatocellular and cholangiocarcinoma patients with extrahepatic metastases: preliminary findings. Liver Int 2006;26:781-8. [DOI: 10.1111/j.1478-3231.2006.01296.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 2.1] [Reference Citation Analysis]
31 Takemoto K, Hatano E, Nishii R, Kagawa S, Kishibe Y, Takahashi M, Yamauchi H, Matsumura K, Zaima M, Toriguchi K, Tanabe K, Kitamura K, Seo S, Taura K, Endo K, Uemoto S, Higashi T. Assessment of [(18)F]-fluoroacetate PET/CT as a tumor-imaging modality: preclinical study in healthy volunteers and clinical evaluation in patients with liver tumor. Ann Nucl Med 2014;28:371-80. [PMID: 24599824 DOI: 10.1007/s12149-014-0823-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
32 Böhm B, Voth M, Geoghegan J, Hellfritzsch H, Petrovich A, Scheele J, Gottschild D. Impact of positron emission tomography on strategy in liver resection for primary and secondary liver tumors. J Cancer Res Clin Oncol. 2004;130:266-272. [PMID: 14767761 DOI: 10.1007/s00432-003-0527-6] [Cited by in Crossref: 66] [Cited by in F6Publishing: 51] [Article Influence: 3.7] [Reference Citation Analysis]
33 Kornberg A, Schernhammer M, Friess H. 18F-FDG-PET for Assessing Biological Viability and Prognosis in Liver Transplant Patients with Hepatocellular Carcinoma. J Clin Transl Hepatol 2017;5:224-34. [PMID: 28936404 DOI: 10.14218/JCTH.2017.00014] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
34 Mccarville MB, Roebuck DJ. Diagnosis and staging of hepatoblastoma: Imaging aspects. Pediatr Blood Cancer 2012;59:793-9. [DOI: 10.1002/pbc.24221] [Cited by in Crossref: 31] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
35 Chafey P, Finzi L, Boisgard R, Caüzac M, Clary G, Broussard C, Pégorier JP, Guillonneau F, Mayeux P, Camoin L. Proteomic analysis of beta-catenin activation in mouse liver by DIGE analysis identifies glucose metabolism as a new target of the Wnt pathway. Proteomics. 2009;9:3889-3900. [PMID: 19639598 DOI: 10.1002/pmic.200800609] [Cited by in Crossref: 59] [Cited by in F6Publishing: 60] [Article Influence: 4.5] [Reference Citation Analysis]
36 Lin CY, Chen JH, Liang JA, Lin CC, Jeng LB, Kao CH. 18F-FDG PET or PET/CT for detecting extrahepatic metastases or recurrent hepatocellular carcinoma: a systematic review and meta-analysis. Eur J Radiol 2012;81:2417-22. [PMID: 21899970 DOI: 10.1016/j.ejrad.2011.08.004] [Cited by in Crossref: 61] [Cited by in F6Publishing: 53] [Article Influence: 5.5] [Reference Citation Analysis]
37 Lee JW, Yun M, Cho A, Han KH, Kim DY, Lee SM, Lee JD. The predictive value of metabolic tumor volume on FDG PET/CT for transarterial chemoembolization and transarterial chemotherapy infusion in hepatocellular carcinoma patients without extrahepatic metastasis. Ann Nucl Med. 2015;29:400-408. [PMID: 25652647 DOI: 10.1007/s12149-015-0956-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
38 Talbot J, Michaud L, Grange J, Rosmorduc O, Balogova S. Use of choline PET for studying hepatocellular carcinoma. Clin Transl Imaging 2014;2:103-13. [DOI: 10.1007/s40336-014-0055-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
39 Hu XG, Shen XY, Nan JN, Kim IG, Yoon JK, Hong SY, Kim MN, Kim BW, Wang HJ. 18F-fluorodeoxyglucose PET/CT as an independent predictor for patients with hepatocellular carcinoma combined with major portal vein tumor thrombus. Ann Surg Treat Res 2020;99:8-17. [PMID: 32676477 DOI: 10.4174/astr.2020.99.1.8] [Reference Citation Analysis]
40 Talbot JN, Fartoux L, Balogova S, Nataf V, Kerrou K, Gutman F, Huchet V, Ancel D, Grange JD, Rosmorduc O. Detection of hepatocellular carcinoma with PET/CT: A prospective comparison of 18F-fluorocholine and 18F-FDG in patients with cirrhosis or chronic liver disease. J Nucl Med. 2010;51:1699-1706. [PMID: 20956466 DOI: 10.2967/jnumed.110.075507] [Cited by in Crossref: 129] [Cited by in F6Publishing: 104] [Article Influence: 10.8] [Reference Citation Analysis]
41 Na SJ, Oh JK, Hyun SH, Lee JW, Hong IK, Song BI, Kim TS, Eo JS, Lee SW, Yoo IR, Chung YA, Yun M. 18F-FDG PET/CT Can Predict Survival of Advanced Hepatocellular Carcinoma Patients: A Multicenter Retrospective Cohort Study. J Nucl Med. 2017;58:730-736. [PMID: 27789714 DOI: 10.2967/jnumed.116.182022] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
42 Guo W, Pang Y, Yao L, Zhao L, Fan C, Ke J, Guo P, Hao B, Fu H, Xie C, Lin Q, Wu H, Sun L, Chen H. Imaging fibroblast activation protein in liver cancer: a single-center post hoc retrospective analysis to compare [68Ga]Ga-FAPI-04 PET/CT versus MRI and [18F]-FDG PET/CT. Eur J Nucl Med Mol Imaging 2021;48:1604-17. [DOI: 10.1007/s00259-020-05095-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
43 Annovazzi A, Peeters M, Maenhout A, Signore A, Dierckx R, Van De Wiele C. 18-fluorodeoxyglucose positron emission tomography in nonendocrine neoplastic disorders of the gastrointestinal tract. Gastroenterology 2003;125:1235-45. [PMID: 14517805 DOI: 10.1016/s0016-5085(03)01208-3] [Cited by in Crossref: 22] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
44 Horowitz JM, Kamel IR, Arif-tiwari H, Asrani SK, Hindman NM, Kaur H, Mcnamara MM, Noto RB, Qayyum A, Lalani T. ACR Appropriateness Criteria ® Chronic Liver Disease. Journal of the American College of Radiology 2017;14:S391-405. [DOI: 10.1016/j.jacr.2017.08.045] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
45 Eo JS, Paeng JC, Lee DS. Nuclear imaging for functional evaluation and theragnosis in liver malignancy and transplantation. World J Gastroenterol 2014; 20(18): 5375-5388 [PMID: 24833867 DOI: 10.3748/wjg.v20.i18.5375] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
46 Lee JW, Oh JK, Chung YA, Na SJ, Hyun SH, Hong IK, Eo JS, Song BI, Kim TS, Kim do Y. Prognostic Significance of 18F-FDG Uptake in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization or Concurrent Chemoradiotherapy: A Multicenter Retrospective Cohort Study. J Nucl Med. 2016;57:509-516. [PMID: 26742711 DOI: 10.2967/jnumed.115.167338] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
47 Fartoux L, Balogova S, Nataf V, Kerrou K, Huchet V, Rosmorduc O, Talbot JN. A pilot comparison of 18F-fluorodeoxyglucose and 18F-fluorocholine PET/CT to predict early recurrence of unifocal hepatocellular carcinoma after surgical resection. Nucl Med Commun. 2012;33:757-765. [PMID: 22504293 DOI: 10.1097/mnm.0b013e328350fb9f] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
48 Takeuchi S, Rohren EM, Abdel-Wahab R, Xiao L, Morris JS, Macapinlac HA, Hassan MM, Kaseb AO. Refining prognosis in patients with hepatocellular carcinoma through incorporation of metabolic imaging biomarkers. Eur J Nucl Med Mol Imaging 2017;44:969-78. [PMID: 27942837 DOI: 10.1007/s00259-016-3583-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
49 Yamamoto Y, Nishiyama Y, Kameyama R, Okano K, Kashiwagi H, Deguchi A, Kaji M, Ohkawa M. Detection of hepatocellular carcinoma using 11C-choline PET: comparison with 18F-FDG PET. J Nucl Med. 2008;49:1245-1248. [PMID: 18632827 DOI: 10.2967/jnumed.108.052639] [Cited by in Crossref: 84] [Cited by in F6Publishing: 77] [Article Influence: 6.0] [Reference Citation Analysis]
50 Tétreau R, Llacer C, Riou O, Deshayes E. Evaluation of response after SBRT for liver tumors. Rep Pract Oncol Radiother 2017;22:170-5. [PMID: 28490989 DOI: 10.1016/j.rpor.2015.12.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
51 Ariff B, Lloyd CR, Khan S, Shariff M, Thillainayagam AV, Bansi DS, Khan SA, Taylor-Robinson SD, Lim AK. Imaging of liver cancer. World J Gastroenterol 2009; 15(11): 1289-1300 [PMID: 19294758 DOI: 10.3748/wjg.15.1289] [Cited by in CrossRef: 71] [Cited by in F6Publishing: 50] [Article Influence: 5.5] [Reference Citation Analysis]
52 Talbot JN, Gutman F, Fartoux L, Grange JD, Ganne N, Kerrou K, Grahek D, Montravers F, Poupon R, Rosmorduc O. PET/CT in patients with hepatocellular carcinoma using [(18)F]fluorocholine: preliminary comparison with [(18)F]FDG PET/CT. Eur J Nucl Med Mol Imaging. 2006;33:1285-1289. [PMID: 16802155 DOI: 10.1007/s00259-006-0164-9] [Cited by in Crossref: 99] [Cited by in F6Publishing: 85] [Article Influence: 6.2] [Reference Citation Analysis]
53 Salem N, Kuang Y, Corn D, Erokwu B, Kolthammer JA, Tian H, Wu C, Wang F, Wang Y, Lee Z. [(Methyl)1-(11)c]-acetate metabolism in hepatocellular carcinoma. Mol Imaging Biol. 2011;13:140-151. [PMID: 20401538 DOI: 10.1007/s11307-010-0308-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
54 Weber S, Jarnagin W, Duffy A, O'reilly EM, Abou-alfa GK, Blumgart L. Liver and Bile Duct Cancer. Abeloff's Clinical Oncology. Elsevier; 2008. pp. 1569-94. [DOI: 10.1016/b978-0-443-06694-8.50088-9] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
55 Salem N, MacLennan GT, Kuang Y, Anderson PW, Schomisch SJ, Tochkov IA, Tennant BC, Lee Z. Quantitative evaluation of 2-deoxy-2[F-18]fluoro-D-glucose-positron emission tomography imaging on the woodchuck model of hepatocellular carcinoma with histological correlation. Mol Imaging Biol. 2007;9:135-143. [PMID: 17308952 DOI: 10.1007/s11307-007-0092-5] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
56 Murakami K. FDG-PET for hepatobiliary and pancreatic cancer: Advances and current limitations. World J Clin Oncol 2011; 2(5): 229-236 [PMID: 21611100 DOI: 10.5306/wjco.v2.i5.229] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
57 Shao YY, Hsu CH, Cheng AL. Predictive biomarkers of sorafenib efficacy in advanced hepatocellular carcinoma: Are we getting there? World J Gastroenterol 2015; 21(36): 10336-10347 [PMID: 26420960 DOI: 10.3748/wjg.v21.i36.10336] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 24] [Article Influence: 3.6] [Reference Citation Analysis]
58 Mandelkern M, Raines J. Positron Emission Tomography in Cancer Research and Treatment. Technol Cancer Res Treat 2002;1:423-39. [DOI: 10.1177/153303460200100603] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
59 Kasuya T, Tateishi U, Suzuki K, Daisaki H, Nishiyama Y, Hata M, Inoue T. Role of respiratory-gated PET/CT for pancreatic tumors: a preliminary result. Eur J Radiol. 2013;82:69-74. [PMID: 23068562 DOI: 10.1016/j.ejrad.2012.05.037] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
60 Yeh MM, Yeung RS, Apisarnthanarax S, Bhattacharya R, Cuevas C, Harris WP, Hon TLK, Padia SA, Park JO, Riggle KM, Daoud SS. Multidisciplinary perspective of hepatocellular carcinoma: A Pacific Northwest experience. World J Hepatol 2015; 7(11): 1460-1483 [PMID: 26085907 DOI: 10.4254/wjh.v7.i11.1460] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
61 Song J, Lee YN, Kim YS, Kim SG, Jin SJ, Park JM, Choi GS, Chung JC, Lee MH, Cho YH, Choi MH, Kim DC, Choi HJ, Moon JH, Lee SH, Jeong SW, Jang JY, Kim HS, Kim BS. Predictability of preoperative 18F-FDG PET for histopathological differentiation and early recurrence of primary malignant intrahepatic tumors. Nuclear Medicine Communications 2015;36:319-27. [DOI: 10.1097/mnm.0000000000000254] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
62 Roivainen A, Naum A, Nuutinen H, Leino R, Nurmi H, Någren K, Parkkola R, Virtanen J, Kallajoki M, Kujari H, Ovaska J, Roberts P, Seppänen M. Characterization of hepatic tumors using [11C]metomidate through positron emission tomography: comparison with [11C]acetate. EJNMMI Res 2013;3:13. [PMID: 23442595 DOI: 10.1186/2191-219X-3-13] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
63 Xia H, Chen J, Gao H, Kong SN, Deivasigamani A, Shi M, Xie T, Hui KM. Hypoxia-induced modulation of glucose transporter expression impacts 18F-fluorodeoxyglucose PET-CT imaging in hepatocellular carcinoma. Eur J Nucl Med Mol Imaging 2020;47:787-97. [PMID: 31832727 DOI: 10.1007/s00259-019-04638-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
64 Chen H, Zhao L, Ruan D, Pang Y, Hao B, Dai Y, Wu X, Guo W, Fan C, Wu J, Huang W, Lin Q, Sun L, Wu H. Usefulness of [68Ga]Ga-DOTA-FAPI-04 PET/CT in patients presenting with inconclusive [18F]FDG PET/CT findings. Eur J Nucl Med Mol Imaging 2021;48:73-86. [DOI: 10.1007/s00259-020-04940-6] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 14.5] [Reference Citation Analysis]
65 Lan BY, Kwee SA, Wong LL. Positron emission tomography in hepatobiliary and pancreatic malignancies: a review. Am J Surg. 2012;204:232-241. [PMID: 22464445 DOI: 10.1016/j.amjsurg.2011.07.025] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
66 Anderson GS, Brinkmann F, Soulen MC, Alavi A, Zhuang H. FDG positron emission tomography in the surveillance of hepatic tumors treated with radiofrequency ablation. Clin Nucl Med. 2003;28:192-197. [PMID: 12592125 DOI: 10.1097/01.rlu.0000053530.95952.fd] [Cited by in Crossref: 58] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
67 Hatori A, Yui J, Xie L, Kumata K, Yamasaki T, Fujinaga M, Wakizaka H, Ogawa M, Nengaki N, Kawamura K, Wang F, Zhang MR. Utility of Translocator Protein (18 kDa) as a Molecular Imaging Biomarker to Monitor the Progression of Liver Fibrosis. Sci Rep 2015;5:17327. [PMID: 26612465 DOI: 10.1038/srep17327] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 3.1] [Reference Citation Analysis]
68 Abouzied MM, Alhinti N, AlMuhaideb A, Al Sugair AS, Al Qahtani M. Extrahepatic metastases from hepatocellular carcinoma: multimodality image evaluation. Nucl Med Commun 2021;42:583-91. [PMID: 33625188 DOI: 10.1097/MNM.0000000000001380] [Reference Citation Analysis]
69 Li L, Che L, Wang C, Blecha JE, Li X, VanBrocklin HF, Calvisi DF, Puchowicz M, Chen X, Seo Y. [(11)C]acetate PET Imaging is not Always Associated with Increased Lipogenesis in Hepatocellular Carcinoma in Mice. Mol Imaging Biol. 2016;18:360-367. [PMID: 26567114 DOI: 10.1007/s11307-015-0915-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
70 Kornberg A, Friess H. 18F-fludeoxyglucose positron emission tomography for diagnosis of HCC: implications for therapeutic strategy in curative and non-curative approaches. Therap Adv Gastroenterol 2019;12:1756284819836205. [PMID: 30915167 DOI: 10.1177/1756284819836205] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
71 Cho KJ, Choi NK, Shin MH, Chong AR. Clinical usefulness of FDG-PET in patients with hepatocellular carcinoma undergoing surgical resection. Ann Hepatobiliary Pancreat Surg. 2017;21:194-198. [PMID: 29264581 DOI: 10.14701/ahbps.2017.21.4.194] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
72 Shiomi S, Kawabe J. Clinical applications of positron emission tomography in hepatic tumors. Hepatol Res. 2011;41:611-617. [PMID: 21711419 DOI: 10.1111/j.1872-034x.2011.00819.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
73 Koch W, Tatsch K. Nuclear Medicine Procedures for Treatment Evaluation. In: Bilbao JI, Reiser MF, editors. Liver Radioembolization with 90Y Microspheres. Berlin: Springer Berlin Heidelberg; 2008. pp. 75-91. [DOI: 10.1007/978-3-540-35423-9_8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
74 Dubash SR, Idowu OA, Sharma R. The emerging role of positron emission tomography in hepatocellular carcinoma. Hepat Oncol. 2015;2:191-200. [PMID: 30190998 DOI: 10.2217/hep.15.6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
75 Larsson P, Arvidsson D, Björnstedt M, Isaksson B, Jersenius U, Motarjemi H, Jacobsson H. Adding 11C-acetate to 18F-FDG at PET Examination Has an Incremental Value in the Diagnosis of Hepatocellular Carcinoma. Mol Imaging Radionucl Ther 2012;21:6-12. [PMID: 23487415 DOI: 10.4274/Mirt.87] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 1.1] [Reference Citation Analysis]
76 Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, Kudo M, Lee JM, Choi BI, Poon RT, Shiina S, Cheng AL, Jia JD, Obi S, Han KH, Jafri W, Chow P, Lim SG, Chawla YK, Budihusodo U, Gani RA, Lesmana CR, Putranto TA, Liaw YF, Sarin SK. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int. 2010;4:439-474. [PMID: 20827404 DOI: 10.1007/s12072-010-9165-7] [Cited by in Crossref: 684] [Cited by in F6Publishing: 685] [Article Influence: 57.0] [Reference Citation Analysis]
77 Puranik AD, Rangarajan V, Gosavi A, Shetty N, Gala K, Kulkarni S, Mohite A, Patkar S, Goel M, Shrikhande SV, Ramaswamy A, Ostwal V, Purandare NC, Agrawal A, Shah S. Prognostic value of imaging-based parameters in patients with intermediate-stage hepatocellular carcinoma undergoing transarterial radioembolization. Nucl Med Commun 2021;42:337-44. [PMID: 33306631 DOI: 10.1097/MNM.0000000000001334] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
78 Filippi L, Di Costanzo GG, D’agostini A, Tortora R, Pelle G, Cianni R, Schillaci O, Bagni O. Decrease in total lesion glycolysis and survival after yttrium-90-radioembolization in poorly differentiated hepatocellular carcinoma with portal vein tumour thrombosis. Nuclear Medicine Communications 2018;39:845-52. [DOI: 10.1097/mnm.0000000000000879] [Cited by in Crossref: 6] [Article Influence: 1.5] [Reference Citation Analysis]
79 Yoon KT, Kim JK, Kim DY, Ahn SH, Lee JD, Yun M, Rha SY, Chon CY, Han KH. Role of 18F-fluorodeoxyglucose positron emission tomography in detecting extrahepatic metastasis in pretreatment staging of hepatocellular carcinoma. Oncology. 2007;72 Suppl 1:104-110. [PMID: 18087190 DOI: 10.1159/000111715] [Cited by in Crossref: 78] [Cited by in F6Publishing: 66] [Article Influence: 5.2] [Reference Citation Analysis]
80 Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology. 2004;231:305-332. [PMID: 15044750 DOI: 10.1148/radiol.2312021185] [Cited by in Crossref: 541] [Cited by in F6Publishing: 452] [Article Influence: 30.1] [Reference Citation Analysis]
81 Hatano E, Ikai I, Higashi T, Teramukai S, Torizuka T, Saga T, Fujii H, Shimahara Y. Preoperative positron emission tomography with fluorine-18-fluorodeoxyglucose is predictive of prognosis in patients with hepatocellular carcinoma after resection. World J Surg. 2006;30:1736-1741. [PMID: 16850145 DOI: 10.1007/s00268-005-0791-5] [Cited by in Crossref: 75] [Cited by in F6Publishing: 72] [Article Influence: 4.7] [Reference Citation Analysis]
82 Kucuk ON, Soydal C, Araz M, Bilgic S, Ibis E. Prognostic importance of 18F-FDG uptake pattern of hepatocellular cancer patients who received SIRT. Clin Nucl Med. 2013;38:e283-e289. [PMID: 23531737 DOI: 10.1097/rlu.0b013e3182867f17] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
83 Zhang H, Cai H, Lu X, Muzik O, Peng F. Positron emission tomography of human hepatocellular carcinoma xenografts in mice using copper (II)-64 chloride as a tracer. Acad Radiol. 2011;18:1561-1568. [PMID: 22055798 DOI: 10.1016/j.acra.2011.08.006] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
84 Shi X, Xing H, Yang X, Li F, Yao S, Congwei J, Zhao H, Hacker M, Huo L, Li X. Comparison of PET imaging of activated fibroblasts and 18F-FDG for diagnosis of primary hepatic tumours: a prospective pilot study. Eur J Nucl Med Mol Imaging 2021;48:1593-603. [PMID: 33097975 DOI: 10.1007/s00259-020-05070-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
85 Wang H, Zhu W, Ren S, Kong Y, Huang Q, Zhao J, Guan Y, Jia H, Chen J, Lu L, Xie F, Qin L. 68Ga-FAPI-04 Versus 18F-FDG PET/CT in the Detection of Hepatocellular Carcinoma. Front Oncol 2021;11:693640. [PMID: 34249748 DOI: 10.3389/fonc.2021.693640] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
86 Kim SH, Won KS, Choi BW, Jo I, Zeon SK, Chung WJ, Kwon JH. Usefulness of F-18 FDG PET/CT in the Evaluation of Early Treatment Response After Interventional Therapy for Hepatocellular Carcinoma. Nucl Med Mol Imaging. 2012;46:102-110. [PMID: 24900042 DOI: 10.1007/s13139-012-0138-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
87 Yamashige D, Kawamura Y, Kobayashi M, Shindoh J, Kobayashi Y, Okubo S, Muraishi N, Kajiwara A, Iritani S, Fujiyama S, Hosaka T, Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Ikeda K, Arase Y, Hashimoto M, Kumada H. Potential and Clinical Significance of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Evaluating Liver Cancer Response to Lenvatinib Treatment. Oncology 2021;99:169-76. [PMID: 33207358 DOI: 10.1159/000510754] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
88 Lin CY, Liao CW, Chu LY, Yen KY, Jeng LB, Hsu CN, Lin CL, Kao CH. Predictive Value of 18F-FDG PET/CT for Vascular Invasion in Patients With Hepatocellular Carcinoma Before Liver Transplantation. Clin Nucl Med. 2017;42:e183-e187. [PMID: 28114226 DOI: 10.1097/rlu.0000000000001545] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
89 Costelloe CM, Chuang HH, Madewell JE. FDG PET for the Detection of Bone Metastases: Sensitivity, Specificity and Comparison with Other Imaging Modalities. PET Clin 2010;5:281-95. [PMID: 27157834 DOI: 10.1016/j.cpet.2010.04.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
90 Horowitz JM, Kamel IR, Arif-tiwari H, Asrani SK, Hindman NM, Kaur H, Mcnamara MM, Noto RB, Qayyum A, Lalani T. ACR Appropriateness Criteria ® Chronic Liver Disease. Journal of the American College of Radiology 2017;14:S103-17. [DOI: 10.1016/j.jacr.2017.02.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
91 Jadvar H. Hepatocellular carcinoma and gastroenteropancreatic neuroendocrine tumors: Potential role of other positron emission tomography radiotracers. Semin Nucl Med. 2012;42:247-254. [PMID: 22681673 DOI: 10.1053/j.semnuclmed.2012.02.001] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
92 Levy CS, Costa FGB, Faria DP, Stefano JT, Cogliati B, Oliveira CP. 18F-FDG PET/CT as an assessment tool of hepatocellular carcinoma secondary to non-alcoholic fatty liver disease development in experimental model.Arq Gastroenterol. 2019;56:45-50. [PMID: 31141073 DOI: 10.1590/S0004-2803.201900000-02] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
93 Kim MJ, Kim YS, Cho YH, Jang HY, Song JY, Lee SH, Jeong SW, Kim SG, Jang JY, Kim HS, Kim BS, Lee WH, Park JM, Lee JM, Lee MH, Choi DL. Use of (18)F-FDG PET to predict tumor progression and survival in patients with intermediate hepatocellular carcinoma treated by transarterial chemoembolization. Korean J Intern Med. 2015;30:308-315. [PMID: 25995661 DOI: 10.3904/kjim.2015.30.3.308] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
94 Blake MA, Singh A, Setty BN, Slattery J, Kalra M, Maher MM, Sahani DV, Fischman AJ, Mueller PR. Pearls and Pitfalls in Interpretation of Abdominal and Pelvic PET-CT. RadioGraphics 2006;26:1335-53. [DOI: 10.1148/rg.265055208] [Cited by in Crossref: 71] [Cited by in F6Publishing: 55] [Article Influence: 4.4] [Reference Citation Analysis]
95 Kim JW, Seong J, Yun M, Lee IJ, Yoon HI, Cho HJ, Han KH. Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose in predicting treatment response in unresectable hepatocellular carcinoma patients treated with external beam radiotherapy. Int J Radiat Oncol Biol Phys. 2012;82:1172-1178. [PMID: 21570203 DOI: 10.1016/j.ijrobp.2010.11.076] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
96 Wachsmann J, Peng F. Molecular imaging and therapy targeting copper metabolism in hepatocellular carcinoma. World J Gastroenterol 2016; 22(1): 221-231 [PMID: 26755872 DOI: 10.3748/wjg.v22.i1.221] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
97 Goh V, Sarker D, Osmany S, Cook GJ. Functional imaging techniques in hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2012;39:1070-1079. [PMID: 22434049 DOI: 10.1007/s00259-012-2096-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
98 Sharma B, Martin A, Zerizer I. Positron Emission Tomography-Computed Tomography in Liver Imaging. Seminars in Ultrasound, CT and MRI 2013;34:66-80. [DOI: 10.1053/j.sult.2012.11.006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
99 Lee JD, Yun M, Lee JM, Choi Y, Choi YH, Kim JS, Kim SJ, Kim KS, Yang WI, Park YN. Analysis of gene expression profiles of hepatocellular carcinomas with regard to 18F-fluorodeoxyglucose uptake pattern on positron emission tomography. Eur J Nucl Med Mol Imaging. 2004;31:1621-1630. [PMID: 15278306 DOI: 10.1007/s00259-004-1602-1] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 3.2] [Reference Citation Analysis]
100 Liu E, Wang S, Lai P, Lian Z, Wang S. “Hepatic Superscan” in a Patient With Hepatosplenic Alphabeta T-cell Lymphoma: 18F-FDG PET/CT Findings. Clin Nucl Med 2018;43:595-8. [DOI: 10.1097/rlu.0000000000002134] [Cited by in Crossref: 10] [Article Influence: 2.5] [Reference Citation Analysis]
101 Oh M, Baek S, Lee SO, Yu E, Ryu JS. A Case of Acute Q Fever Hepatitis Diagnosed by F-18 FDG PET/CT. Nucl Med Mol Imaging 2012;46:125-8. [PMID: 24900046 DOI: 10.1007/s13139-012-0130-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
102 Philip I, Shun A, Mccowage G, Howman-giles R. Positron emission tomography in recurrent hepatoblastoma. Ped Surgery Int 2005;21:341-5. [DOI: 10.1007/s00383-005-1406-9] [Cited by in Crossref: 29] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
103 Grassi I, Morigi JJ, Nanni C, Fanti S. FDG and other radiopharmaceuticals in the evaluation of liver lesions. Clin Transl Imaging 2014;2:115-27. [DOI: 10.1007/s40336-014-0059-x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
104 Yeh C, Chen M, Jen L. Resection of peritoneal implantation from hepatocellular carcinoma. Annals of Surgical Oncology 2002;9:863-8. [DOI: 10.1007/bf02557522] [Cited by in Crossref: 28] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
105 Xia Q, Feng Y, Wu C, Huang G, Liu J, Chen T, Sun X, Song S, Tong L, Ni Y. Differentiation between Malignant and Benign Solitary Lesions in the Liver with (18)FDG PET/CT: Accuracy of Age-related Diagnostic Standard. J Cancer 2015;6:40-7. [PMID: 25553087 DOI: 10.7150/jca.10422] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
106 von Falck C, Rodt T, Shin H, Knapp WH, Galanski M. F-18 FDG PET Imaging of Fibrolamellar Hepatocellular Carcinoma. Clinical Nuclear Medicine 2008;33:633-4. [DOI: 10.1097/rlu.0b013e318181305c] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
107 Hwang KH, Choi DJ, Lee SY, Lee MK, Choe W. Evaluation of patients with hepatocellular carcinomas using [(11) C] acetate and [(18) F] FDG PET/CT: A preliminary study. Appl Radiat Isot. 2009;67:1195-1198. [PMID: 19342249 DOI: 10.1016/j.apradiso.2009.02.011] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 2.6] [Reference Citation Analysis]
108 Braren R, Altomonte J, Settles M, Neff F, Esposito I, Ebert O, Schwaiger M, Rummeny E, Steingoetter A. Validation of preclinical multiparametric imaging for prediction of necrosis in hepatocellular carcinoma after embolization. J Hepatol. 2011;55:1034-1040. [PMID: 21354233 DOI: 10.1016/j.jhep.2011.01.049] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 2.6] [Reference Citation Analysis]
109 Chen R, Li J, Zhou X, Liu J, Huang G. Fructose-1,6-Bisphosphatase 1 Reduces 18F FDG Uptake in Hepatocellular Carcinoma. Radiology 2017;284:844-53. [PMID: 28387640 DOI: 10.1148/radiol.2017161607] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
110 Mcdermott S, Skehan SJ. Whole body imaging in the abdominal cancer patient: pitfalls of PET-CT. Abdom Imaging 2010;35:55-69. [DOI: 10.1007/s00261-008-9493-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
111 Talbot J, Montravers F, Gutman F, Kerrou K, Huchet V, Grahek D, Andre T, Houry S, Touboul E, Rosmorduc O, Poupon R, Ruszniewski P, Rougier P, Grange J. Tomographie par émission de positons et cancers digestifs. La Presse Médicale 2008;37:e1-e24. [DOI: 10.1016/j.lpm.2007.03.048] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
112 Eckel F, Herrmann K, Schmidt S, Hillerer C, Wieder HA, Krause BJ, Schuster T, Langer R, Wester HJ, Schmid RM. Imaging of proliferation in hepatocellular carcinoma with the in vivo marker 18F-fluorothymidine. J Nucl Med. 2009;50:1441-1447. [PMID: 19690030 DOI: 10.2967/jnumed.109.065896] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 2.8] [Reference Citation Analysis]
113 Higashi T, Hatano E, Ikai I, Nishii R, Nakamoto Y, Ishizu K, Suga T, Kawashima H, Togashi K, Seo S, Kitamura K, Takada Y, Kamimoto S. FDG PET as a prognostic predictor in the early post-therapeutic evaluation for unresectable hepatocellular carcinoma. Eur J Nucl Med Mol Imaging 2010;37:468-82. [DOI: 10.1007/s00259-009-1284-9] [Cited by in Crossref: 45] [Cited by in F6Publishing: 35] [Article Influence: 3.5] [Reference Citation Analysis]
114 Sarma M, Padma S, Pavithran P, Somasundaram VH, Sundaram PS. Extrahepatic metastases of hepatocellular carcinoma on 18F FDG PET CT. J Egypt Natl Canc Inst 2021;33:36. [PMID: 34825288 DOI: 10.1186/s43046-021-00086-0] [Reference Citation Analysis]
115 Pan JH, Dong MJ, Ouyang XB. A hepatoid adenocarcinoma of the stomach with liver metastasis mimicking hepatocellular carcinoma detected by F-18 FDG PET/CT imaging. Clin Nucl Med. 2011;36:1137-1139. [PMID: 22064094 DOI: 10.1097/rlu.0b013e3182335ef9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
116 Braat AJ, Huijbregts JE, Molenaar IQ, Borel Rinkes IH, van den Bosch MA, Lam MG. Hepatic radioembolization as a bridge to liver surgery. Front Oncol. 2014;4:199. [PMID: 25126539 DOI: 10.3389/fonc.2014.00199] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
117 Kim HO, Kim JS, Shin YM, Ryu JS, Lee YS, Lee SG. Evaluation of metabolic characteristics and viability of lipiodolized hepatocellular carcinomas using 18F-FDG PET/CT. J Nucl Med. 2010;51:1849-1856. [PMID: 21098794 DOI: 10.2967/jnumed.110.079244] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
118 Lee JW, Hwang SH, Kim DY, Han KH, Yun M. Prognostic Value of FDG Uptake of Portal Vein Tumor Thrombosis in Patients With Locally Advanced Hepatocellular Carcinoma. Clin Nucl Med. 2017;42:e35-e40. [PMID: 27775940 DOI: 10.1097/rlu.0000000000001422] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
119 Kawamura E, Shiomi S, Kotani K, Kawabe J, Hagihara A, Fujii H, Uchida-Kobayashi S, Iwai S, Morikawa H, Enomoto M, Murakami Y, Tamori A, Kawada N. Positioning of 18F-fluorodeoxyglucose-positron emission tomography imaging in the management algorithm of hepatocellular carcinoma. J Gastroenterol Hepatol 2014;29:1722-7. [PMID: 24730671 DOI: 10.1111/jgh.12611] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
120 Young RS, Aldiwani M, Hakeem AR, Nair A, Guthrie A, Wyatt J, Treanor D, Morris-Stiff G, Jones RL, Prasad KR. Pre-liver transplant biopsy in hepatocellular carcinoma: a potential criterion for exclusion from transplantation? HPB (Oxford). 2013;15:418-427. [PMID: 23458127 DOI: 10.1111/hpb.12008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
121 Sotiropoulos GC, Kuehl H, Sgourakis G, Molmenti EP, Beckebaum S, Cicinnati VR, Baba HA, Schmitz KJ, Broelsch CE, Lang H. Pulmonary nodules at risk in patients undergoing liver transplantation for hepatocellular carcinoma. Transplant International 2008;21:850-6. [DOI: 10.1111/j.1432-2277.2008.00688.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
122 Seo HJ, Choi YJ, Kim HJ, Jeong YH, Cho A, Lee JH, Yun M, Choi HJ, Lee JD, Kang WJ. Evaluation of Bone Metastasis from Hepatocellular Carcinoma Using (18)F-FDG PET/CT and (99m)Tc-HDP Bone Scintigraphy: Characteristics of Soft Tissue Formation. Nucl Med Mol Imaging 2011;45:203-11. [PMID: 24900005 DOI: 10.1007/s13139-011-0099-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
123 Hain SF, Fogelman I. Recent advances in imaging hepatocellular carcinoma: diagnosis, staging and response assessment: functional imaging. Cancer J. 2004;10:121-127. [PMID: 15130271 DOI: 10.1097/00130404-200403000-00007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
124 Adhikari A, Singh P, Mahar KS, Adhikari M, Adhikari B, Zhang MR, Tiwari AK. Mapping of Translocator Protein (18 kDa) in Peripheral Sterile Inflammatory Disease and Cancer through PET Imaging. Mol Pharm 2021;18:1507-29. [PMID: 33645995 DOI: 10.1021/acs.molpharmaceut.1c00002] [Reference Citation Analysis]
125 Cho Y, Lee DH, Lee YB, Lee M, Yoo JJ, Choi WM, Cho YY, Paeng JC, Kang KW, Chung JK, Yu SJ, Lee JH, Yoon JH, Lee HS, Kim YJ. Does 18F-FDG positron emission tomography-computed tomography have a role in initial staging of hepatocellular carcinoma? PLoS One 2014;9:e105679. [PMID: 25153834 DOI: 10.1371/journal.pone.0105679] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
126 Bell M, Turkbey EB, Escorcia FE. Radiomics, Radiogenomics, and Next-Generation Molecular Imaging to Augment Diagnosis of Hepatocellular Carcinoma. Cancer J. 2020;26:108-115. [PMID: 32205534 DOI: 10.1097/ppo.0000000000000435] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
127 Morio K, Kawaoka T, Aikata H, Namba M, Uchikawa S, Kodama K, Ohya K, Fujino H, Nakahara T, Murakami E, Yamauchi M, Tsuge M, Hiramatsu A, Imamura M, Nakamura Y, Akagi M, Awai K, Kobayashi T, Ohdan H, Chayama K. Preoperative PET-CT is useful for predicting recurrent extrahepatic metastasis of hepatocellular carcinoma after resection. Eur J Radiol. 2020;124:108828. [PMID: 31955034 DOI: 10.1016/j.ejrad.2020.108828] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
128 Kamel IR, Bluemke DA. Imaging Evaluation of Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology 2002;13:S173-83. [DOI: 10.1016/s1051-0443(07)61784-9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
129 Lee SM, Kim HS, Lee S, Lee JW. Emerging role of 18F-fluorodeoxyglucose positron emission tomography for guiding management of hepatocellular carcinoma. World J Gastroenterol 2019; 25(11): 1289-1306 [PMID: 30918424 DOI: 10.3748/wjg.v25.i11.1289] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
130 Kwee SA, Hernandez B, Chan O, Wong L. Choline kinase alpha and hexokinase-2 protein expression in hepatocellular carcinoma: association with survival. PLoS One. 2012;7:e46591. [PMID: 23071593 DOI: 10.1371/journal.pone.0046591] [Cited by in Crossref: 64] [Cited by in F6Publishing: 63] [Article Influence: 6.4] [Reference Citation Analysis]
131 Shao YY, Hsu CH, Cheng AL. Predictive biomarkers of antiangiogenic therapy for advanced hepatocellular carcinoma: where are we? Liver Cancer 2013;2:93-107. [PMID: 24159601 DOI: 10.1159/000343845] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
132 Chandra KB, Singhal A. Predictors of Macrovascular Invasion and Extrahepatic Metastasis in Treatment Naive Hepatocellular Carcinoma: When Is [18F] FDG PET/CT Relevant? Nucl Med Mol Imaging 2021;55:293-301. [PMID: 34868378 DOI: 10.1007/s13139-021-00714-6] [Reference Citation Analysis]
133 Bai X, Zhang X, Wang X. Primary Hepatic Neuroendocrine Tumor: Pretherapy and Posttherapy FDG PET/CT Finding. Clin Nucl Med 2019;44:88-90. [DOI: 10.1097/rlu.0000000000002376] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
134 Liao X, Wei J, Li Y, Zhong J, Liu Z, Liao S, Li Q, Wei C. 18F-FDG PET with or without CT in the diagnosis of extrahepatic metastases or local residual/recurrent hepatocellular carcinoma. Medicine (Baltimore). 2018;97:e11970. [PMID: 30142825 DOI: 10.1097/md.0000000000011970] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
135 Kumar R, Chauhan A. Positron emission tomography: clinical applications in oncology. Part 2. Expert Rev Anticancer Ther 2006;6:625-40. [PMID: 16613549 DOI: 10.1586/14737140.6.4.625] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
136 Teefey SA, Hildeboldt CC, Dehdashti F, Siegel BA, Peters MG, Heiken JP, Brown JJ, McFarland EG, Middleton WD, Balfe DM, Ritter JH. Detection of primary hepatic malignancy in liver transplant candidates: prospective comparison of CT, MR imaging, US, and PET. Radiology 2003;226:533-42. [PMID: 12563151 DOI: 10.1148/radiol.2262011980] [Cited by in Crossref: 153] [Cited by in F6Publishing: 119] [Article Influence: 8.1] [Reference Citation Analysis]
137 Lopci E, Torzilli G, Poretti D, de Neto LJS, Donadon M, Rimassa L, Lanza E, Sabongi JG, Ceriani R, Personeni N, Palmisano A, Pedicini V, Comito T, Scorsetti M, Chiti A. Diagnostic accuracy of 11C-choline PET/CT in comparison with CT and/or MRI in patients with hepatocellular carcinoma. Eur J Nucl Med Mol Imaging 2015;42:1399-407. [DOI: 10.1007/s00259-015-3079-5] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
138 Smith TA. Influence of chemoresistance and p53 status on fluoro-2-deoxy-D-glucose incorporation in cancer. Nucl Med Biol 2010;37:51-5. [PMID: 20122668 DOI: 10.1016/j.nucmedbio.2009.08.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
139 Cascales-campos P, Ramírez P, Lopez V, Gonzalez R, Saenz-mateos L, Llacer E, Sánchez Bueno F, Robles R, Pons J, Capel A, Frutos L, Navarro J, Muñoz-ramon P, Parrilla P. Prognostic Value of 18-Fluorodeoxyglucose-Positron Emission Tomography After Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma Undergoing Orthotopic Liver Transplantation. Transplantation Proceedings 2015;47:2374-6. [DOI: 10.1016/j.transproceed.2015.08.026] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
140 Gharib AM, Thomasson D, Li KC. Molecular imaging of hepatocellular carcinoma. Gastroenterology 2004;127:S153-8. [DOI: 10.1053/j.gastro.2004.09.029] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
141 Saar B, Kellner-Weldon F. Radiological diagnosis of hepatocellular carcinoma. Liver Int. 2008;28:189-199. [PMID: 18251978 DOI: 10.1111/j.1478-3231.2007.01655.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 27] [Article Influence: 2.7] [Reference Citation Analysis]
142 Bohlok A, De Grez T, Bouazza F, De Wind R, El-Khoury M, Repullo D, Donckier V. Primary Hepatic Lymphoma Mimicking a Hepatocellular Carcinoma in a Cirrhotic Patient: Case Report and Systematic Review of the Literature. Case Rep Surg 2018;2018:9183717. [PMID: 29850362 DOI: 10.1155/2018/9183717] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
143 Poon RT, Fan ST, O'Suilleabhain CB, Wong J. Aggressive management of patients with extrahepatic and intrahepatic recurrences of hepatocellular carcinoma by combined resection and locoregional therapy. J Am Coll Surg 2002;195:311-8. [PMID: 12229937 DOI: 10.1016/s1072-7515(02)01226-7] [Cited by in Crossref: 80] [Cited by in F6Publishing: 37] [Article Influence: 4.0] [Reference Citation Analysis]
144 Bertagna F, Bertoli M, Bosio G, Biasiotto G, Sadeghi R, Giubbini R, Treglia G. Diagnostic role of radiolabelled choline PET or PET/CT in hepatocellular carcinoma: a systematic review and meta-analysis. Hepatol Int 2014;8:493-500. [PMID: 26202754 DOI: 10.1007/s12072-014-9566-0] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 3.6] [Reference Citation Analysis]
145 Tan CH, Low SC, Thng CH. APASL and AASLD Consensus Guidelines on Imaging Diagnosis of Hepatocellular Carcinoma: A Review. Int J Hepatol. 2011;2011:519783. [PMID: 22007313 DOI: 10.4061/2011/519783] [Cited by in Crossref: 40] [Cited by in F6Publishing: 45] [Article Influence: 3.6] [Reference Citation Analysis]
146 Donadon M, Lopci E, Galvanin J, Giudici S, Del Fabbro D, Lanza E, Pedicini V, Chiti A, Torzilli G. Prognostic Value of Metabolic Imaging Data of 11C-choline PET/CT in Patients Undergoing Hepatectomy for Hepatocellular Carcinoma. Cancers (Basel) 2021;13:472. [PMID: 33530520 DOI: 10.3390/cancers13030472] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
147 Kim BK, Kang WJ, Kim JK, Seong J, Park JY, Kim DY, Ahn SH, Lee DY, Lee KH, Lee JD, Han KH. 18F-fluorodeoxyglucose uptake on positron emission tomography as a prognostic predictor in locally advanced hepatocellular carcinoma. Cancer. 2011;117:4779-4787. [PMID: 21469082 DOI: 10.1002/cncr.26099] [Cited by in Crossref: 40] [Cited by in F6Publishing: 43] [Article Influence: 3.6] [Reference Citation Analysis]
148 Zhang Z, Liu S, Ma H, Nie D, Wen F, Zhao J, Sun A, Yuan G, Su S, Xiang X, Hu P, Tang G. Validation of R-2-[18F]Fluoropropionic Acid as a Potential Tracer for PET Imaging of Liver Cancer. Mol Imaging Biol 2019;21:1127-37. [DOI: 10.1007/s11307-019-01346-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
149 Liangpunsakul S, Agarwal D, Horlander JC, Kieff B, Chalasani N. Positron emission tomography for detecting occult hepatocellular carcinoma in hepatitis C cirrhotics awaiting for liver transplantation. Transplant Proc 2003;35:2995-7. [PMID: 14697959 DOI: 10.1016/j.transproceed.2003.10.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
150 Hayakawa N, Nakamoto Y, Nakatani K, Hatano E, Seo S, Higashi T, Saga T, Uemoto S, Togashi K. Clinical utility and limitations of FDG PET in detecting recurrent hepatocellular carcinoma in postoperative patients. Int J Clin Oncol. 2014;19:1020-1028. [PMID: 24366329 DOI: 10.1007/s10147-013-0653-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
151 Takesh M. The Potential Benefit by Application of Kinetic Analysis of PET in the Clinical Oncology. ISRN Oncol 2012;2012:349351. [PMID: 23326682 DOI: 10.5402/2012/349351] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
152 Bruzzi JF, Truong MT, Marom EM, Mawlawi O, Podoloff DA, Macapinlac HA, Munden RF. Incidental Findings on Integrated PET/CT That Do Not Accumulate 18 F-FDG. American Journal of Roentgenology 2006;187:1116-23. [DOI: 10.2214/ajr.05.0712] [Cited by in Crossref: 30] [Cited by in F6Publishing: 4] [Article Influence: 1.9] [Reference Citation Analysis]
153 Lee JD, Kang WJ, Yun M. Primary Cancer of the Liver and Biliary Duct. PET Clin 2008;3:169-86. [PMID: 27156461 DOI: 10.1016/j.cpet.2008.08.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]